Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 41Terminated 12Unknown 9Active not recruiting 5Recruiting 2Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Neoplasms 2Leukemia 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Tissue Adhesions 1Radiation Injuries 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Pain, Intractable 1Ovarian Neoplasms 1Ovarian Cysts 1Neurotoxicity Syndromes 1Neoplasm Metastasis 1NSCLC 1Multiple Myeloma 1Mucositis 1Malnutrition 1Malignant Female Reproductive System Neoplasm 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Glioblastoma 1Fatigue 1Fasting Mimicking Diet 1Eyelid Squamous Cell Carcinoma 1Endometriosis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Suspended × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Clear all
NCT01755325 2018-04-25

Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+

Ruijin Hospital

Phase 3 Suspended
680 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡